Abstract: The present invention relates to a method and system for predicting performance of biopharmaceutical manufacturing processes by measuring a parameter of the biopharmaceutical manufacturing process at a predetermined sampling frequency, wherein said parameter is measured for n number of runs of said process, sequentially joining the parameter data of the n number of runs in a single continuous time-series manner, to generate a transformed data, training a time series analysis model for forecasting performance of the biopharmaceutical manufacturing process, based on a plurality of transformed data generated corresponding to a plurality of parameters, measuring the plurality of parameters at a predetermined timepoint, and using said measurement to reinforce and improve the trained time series analysis model, and predicting the plurality of parameters for a future run of the biopharmaceutical manufacturing process, based on the trained time series analysis model.

Abstract: Circular mass accelerators for off-world applications are disclosed herein. An example system includes a base assembly that is configured to interface with a supporting surface, a vertical support assembly extending from the base assembly, a first drive positioned, a shaft connected to the first drive, a hub assembly having a spool, the hub assembly being coupled to a second drive that is located on a terminal end of the shaft, a first tether and a second tether that can be spooled onto and unspooled from the spool by the second drive, and payloads positioned each of the tethers, the payloads being releasably coupled to tethers in such a way that the payloads can be released upon the payloads being rotated to a target launch velocity.

Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.

Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Abstract: This disclosure is for an endoluminal delivery cannula, for delivery of a substance to an extravascular target site via the vascular system of a human or animal body, wherein the cannula comprises a proximal cannula hub, an elongated proximal, and a tip portion. The tip is tapered towards the distal tip which is preferably provided with a pointed tip for penetrating tissue. The pointed tip may comprise at least one primary facet and two secondary facets, wherein the two secondary facets are arranged proximally of said primary facet. An endoluminal delivery assembly comprises the cannula, a protective catheter adapted for insertion into the vascular system of a human or animal body, and a proximal catheter hub provided at the proximal end of the catheter and adapted for guiding the catheter through the vascular system.

Abstract: A lattice of hollow bodies for forming a concrete floor slab comprises a plurality of hollow bodies. Each of the hollow bodies is coupled to an adjacent other one of said hollow bodies. Each of the hollow bodies has an outwardly extending reinforcement support for receiving a reinforcement member.

Abstract: Embodiments herein are directed to methods for preparing and compositions containing microalgae biomass. Described herein are, for example, methods of preparing a microalgal flour that involve culturing microalgae, concentrating the microalgae into a microalgal biomass sludge, washing the microalgal biomass sludge, adjusting the pH of the microalgal biomass sludge, and drying the microalgal biomass sludge to produce the microalgal flour. Also disclosed are food products supplemented with microalgae biomass, including for example microalgal flour, a protein concentrate, or a protein isolate.

Abstract: A lattice of hollow bodies for forming a concrete floor slab comprises a plurality of hollow bodies. Each of the hollow bodies is coupled to an adjacent other one of said hollow bodies. Each of the hollow bodies has an outwardly extending reinforcement support for receiving a reinforcement member.

Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

Abstract: Methods of forming a gelatinous food product, forming a whitened food product, increasing viscosity, increasing water binding, emulsifying, or sweetening a food product, comprising combining paramylon from Euglena sp. with a food composition, to form the food product thereof. The disclosure also relates to methods of encapsulating an oil with paramylon, to form an encapsulated oil thereof.

Abstract: The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

Abstract: The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.

Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

Abstract: A vehicle includes a first member inflatable to an inflated position in which the first member has a first and a second distal edge spaced from each other along a vehicle-longitudinal axis. The vehicle includes a second member inflatable to an inflated position, the second member in the inflated position being on a cross-vehicle axis that extends through the first distal edge. The vehicle includes a one-way vent permitting fluid flow from the first member to the second member.

Abstract: Several systems for tracking one or more radiation blocking objects on a surface are disclosed. A pair of radiation sensors are provided adjacent the surface and a plurality of radiation sources are provided adjacent the surface. Radiation from at least some of the radiation sources travels across the surface to reach each of the radiation sensors. One or more radiation blocking objects on the surface attenuate radiation from one or more radiation sources from reaching each of the sensors. The position of the one or more radiation blocking objects is estimates and may be tracked based on the position of the one or more attenuated radiation sources relative to each radiation sensor.

Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.